GlaxoSmithKline | Srodki Pieniężne I Ekwiwalent



Cash And Equivalent Zmiana Data
AbbVie USD 5.18B 349M 2025-03
Alcon AG USD 1.41B 417M 2025-03
Almirall EUR 374.4M 2.7M 2025-03
Amgen USD 8.03B 782M 2025-06
argenx SE 2.09B 586.04M 2025-06
AstraZeneca USD 7.06B 1.83B 2025-06
Bayer EUR 4.56B 542M 2025-06
Biogen USD 2.76B 160.5M 2025-06
Bristol-Myers Squibb USD 12.6B 1.72B 2025-06
Eli Lilly USD 3.38B 282.6M 2025-06
Fresenius EUR 1.23B 1.16B 2025-06
Fresenius Medical Care EUR 1.72B 644.08M 2025-06
Galapagos EUR 108.07M 43.83M 2025-03
Genmab DKK 1.3B 323M 2025-06
Gilead Sciences USD 5.14B 2.78B 2025-06
GlaxoSmithKline GBP 3.6B 865M 2025-06
Glaxosmithkline GBP 3.87B 678M 2024-12
GRIFOLS EUR 558.69M 194.13M 2025-06
Hikma Pharmaceutical USD 188M 188M 2024-12
Lonza CHF 1.11B 286M 2024-12
Merck EUR 1.17B 161M 2025-06
Merck USD 8.01B 622M 2025-06
Novartis USD 6.66B 410M 2025-06
Novo Nordisk A/S 12.65B 15.81B 2022-12
Orion EUR 259.4M 53.8M 2025-03
Pfizer USD 1.64B 208M 2025-06
Philips EUR 1.82B 629M 2025-06
Recordati EUR 341.55M 8.51M 2025-06
Regeneron Pharmaceuticals USD 2B 1.09B 2025-06
Roche Holding CHF 6.98B 2.15B 2024-12
Sanofi 15.36B 7.37B 2025-06
UCB EUR 1.57B 1.14B 2024-12


GlaxoSmithKline Srodki Pieniężne I Ekwiwalent - Aktualne wartości, dane historyczne, prognozy, statystyki, wykresy i kalendarz ekonomiczny - Aug 2025.